State Farm Mutual Automobile Insurance Company Has Increased Colgate Palmolive Co (CL) Stake; Cellular Biomedicine Group (CBMG) Shorts Up By 1.88%

August 27, 2017 – By Marguerite Chambers

Cellular Biomedicine Group Incorporated (NASDAQ:CBMG) had an increase of 1.88% in short interest. CBMG’s SI was 238,000 shares in August as released by FINRA. Its up 1.88% from 233,600 shares previously. With 24,600 avg volume, 10 days are for Cellular Biomedicine Group Incorporated (NASDAQ:CBMG)’s short sellers to cover CBMG’s short positions. The SI to Cellular Biomedicine Group Incorporated’s float is 2.27%. It closed at $8.7 lastly. It is down 51.66% since August 27, 2016 and is downtrending. It has underperformed by 68.36% the S&P500.

State Farm Mutual Automobile Insurance Company increased Colgate Palmolive Co (CL) stake by 2.16% reported in 2016Q4 SEC filing. State Farm Mutual Automobile Insurance Company acquired 184,270 shares as Colgate Palmolive Co (CL)’s stock rose 3.95%. The State Farm Mutual Automobile Insurance Company holds 8.72 million shares with $570.73 million value, up from 8.54 million last quarter. Colgate Palmolive Co now has $62.67B valuation. The stock increased 0.52% or $0.37 on August 25, reaching $71.15. About 2.16 million shares traded. Colgate-Palmolive Company (NYSE:CL) has risen 6.23% since August 27, 2016 and is uptrending. It has underperformed by 10.47% the S&P500.

Cellular Biomedicine Group, Inc. is a biomedicine company. The company has market cap of $122.75 million. The Firm is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell technologies. It currently has negative earnings. The Firm operates in Biomedicine Cell Therapy segment.

Investors sentiment decreased to 1 in Q4 2016. Its down 0.90, from 1.9 in 2016Q3. It fall, as 1 investors sold Cellular Biomedicine Group Inc shares while 9 reduced holdings. 5 funds opened positions while 14 raised stakes. 1.45 million shares or 14.03% more from 1.27 million shares in 2016Q3 were reported. 119,382 are held by Vanguard Inc. California Public Employees Retirement Sys invested 0% in Cellular Biomedicine Group Inc (NASDAQ:CBMG). Manufacturers Life Insurance The reported 9,410 shares or 0% of all its holdings. Bank & Trust Of Mellon Corp reported 39,506 shares. Amer International Group Inc reported 6,991 shares. Schwab Charles Inv Management owns 22,709 shares for 0% of their portfolio. Moreover, Northern Tru Corp has 0% invested in Cellular Biomedicine Group Inc (NASDAQ:CBMG) for 133,312 shares. Zurcher Kantonalbank (Zurich Cantonalbank) invested in 11,371 shares. Citigroup, New York-based fund reported 12,245 shares. Barclays Public Limited Co invested in 145 shares or 0% of the stock. California-based Blackrock Institutional Na has invested 0% in Cellular Biomedicine Group Inc (NASDAQ:CBMG). Creative Planning has invested 0% in Cellular Biomedicine Group Inc (NASDAQ:CBMG). California State Teachers Retirement Sys stated it has 24,998 shares. Meeder Asset Management reported 354 shares. Bnp Paribas Arbitrage has invested 0% in Cellular Biomedicine Group Inc (NASDAQ:CBMG).

Since June 6, 2017, it had 1 buying transaction, and 0 sales for $68,348 activity. 10,000 shares were bought by Liu Tony, worth $68,348 on Tuesday, June 6.

Among 21 analysts covering Colgate-Palmolive (NYSE:CL), 3 have Buy rating, 0 Sell and 18 Hold. Therefore 14% are positive. Colgate-Palmolive had 45 analyst reports since July 21, 2015 according to SRatingsIntel. The stock has “Neutral” rating by UBS on Friday, July 29. Jefferies maintained Colgate-Palmolive Company (NYSE:CL) on Tuesday, August 22 with “Hold” rating. The stock of Colgate-Palmolive Company (NYSE:CL) earned “Buy” rating by Citigroup on Thursday, April 14. The firm has “Neutral” rating given on Friday, July 29 by BNP Paribas. The company was maintained on Friday, July 31 by UBS. The rating was maintained by UBS with “Neutral” on Friday, April 29. The firm earned “Overweight” rating on Wednesday, January 6 by Atlantic Securities. The firm has “Hold” rating given on Tuesday, August 1 by RBC Capital Markets. Jefferies maintained Colgate-Palmolive Company (NYSE:CL) rating on Wednesday, April 19. Jefferies has “Hold” rating and $78 target. Stifel Nicolaus maintained it with “Hold” rating and $70 target in Monday, January 30 report.

Investors sentiment decreased to 0.82 in 2016 Q4. Its down 0.04, from 0.86 in 2016Q3. It dropped, as 53 investors sold CL shares while 472 reduced holdings. 91 funds opened positions while 363 raised stakes. 616.46 million shares or 0.02% less from 616.56 million shares in 2016Q3 were reported. 13,464 were accumulated by Texas Yale. Cadinha & Ltd Llc has invested 0.17% in Colgate-Palmolive Company (NYSE:CL). Guggenheim Capital Limited Liability Co holds 0.2% in Colgate-Palmolive Company (NYSE:CL) or 1.07M shares. Dowling & Yahnke Ltd Liability Corp invested in 78,243 shares or 0.57% of the stock. Smithfield Tru owns 19,372 shares or 0.21% of their US portfolio. Btr holds 0.15% of its portfolio in Colgate-Palmolive Company (NYSE:CL) for 8,727 shares. Jane Street Ltd Co reported 22,173 shares or 0.01% of all its holdings. Weik Inv Services reported 6,470 shares or 0.24% of all its holdings. Ghp Investment Advisors Inc owns 46,763 shares. Moreover, Pinebridge Investments Ltd Partnership has 0.37% invested in Colgate-Palmolive Company (NYSE:CL). Estabrook Cap has invested 0% of its portfolio in Colgate-Palmolive Company (NYSE:CL). California-based Blackrock Fund Advsr has invested 0.16% in Colgate-Palmolive Company (NYSE:CL). Motco accumulated 8,042 shares or 0.06% of the stock. 51,502 are held by Kings Point Capital Mgmt. Country Club Na has invested 0.04% in Colgate-Palmolive Company (NYSE:CL).

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.


Please enter your comment!
Please enter your name here

fourteen + sixteen =